Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Journal of Medicinal Chemistry|December 19, 1998
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)R J Griffin, S Srinivasan, K Bowman, et al.
British Journal of Cancer|January 1, 1997
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell linesE J Estlin, K Balmanno, A H Calvert, et al.
Cancer Treatment Reports|August 1, 1986
Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouseD R Newell, D L Alison, A H Calvert, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2002
A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalationD Fyfe, F Raynaud, R E Langley, et al.
British Journal of Cancer|May 26, 2011
Thiothymidine combined with UVA as a potential novel therapy for bladder cancerS W Pridgeon, R Heer, G A Taylor, et al.
British Journal of Cancer|May 2, 2000
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxelA N Hughes, M J Griffin, D R Newell, et al.
Biochemical Pharmacology|October 24, 1991
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)A L Jackman, D R Newell, W Gibson, et al.
Cancer Research|December 1, 1990
Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordinE J Wawrzynczak, A J Cumber, R V Henry, et al.
Therapeutic Drug Monitoring|September 1, 1987
Propylene glycol pharmacokinetics and effects after intravenous infusion in humansP A Speth, T B Vree, N F Neilen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 daysA N Hughes, I Rafi, M J Griffin, et al.
Pageof 12